Vision Capital Management Inc. Reduces Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Vision Capital Management Inc. decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 43.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,119 shares of the biopharmaceutical company's stock after selling 4,789 shares during the period. Vision Capital Management Inc.'s holdings in Gilead Sciences were worth $565,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the company. Onyx Bridge Wealth Group LLC grew its position in shares of Gilead Sciences by 8.1% in the fourth quarter. Onyx Bridge Wealth Group LLC now owns 5,164 shares of the biopharmaceutical company's stock valued at $477,000 after purchasing an additional 386 shares in the last quarter. Tectonic Advisors LLC increased its holdings in shares of Gilead Sciences by 7.4% in the fourth quarter. Tectonic Advisors LLC now owns 81,286 shares of the biopharmaceutical company's stock worth $7,508,000 after purchasing an additional 5,580 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Gilead Sciences by 8.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 434,165 shares of the biopharmaceutical company's stock valued at $40,689,000 after acquiring an additional 34,549 shares in the last quarter. Y.D. More Investments Ltd boosted its position in shares of Gilead Sciences by 43.3% during the 4th quarter. Y.D. More Investments Ltd now owns 1,602 shares of the biopharmaceutical company's stock valued at $148,000 after acquiring an additional 484 shares during the last quarter. Finally, Hager Investment Management Services LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth approximately $145,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analysts Set New Price Targets

GILD has been the subject of a number of research reports. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an "outperform" rating and a $105.00 price target for the company. The Goldman Sachs Group raised their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a "neutral" rating in a research report on Thursday, November 7th. Morgan Stanley upgraded Gilead Sciences from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $87.00 to $113.00 in a research report on Friday, January 10th. Piper Sandler boosted their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Finally, BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. According to MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $98.39.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the company's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 572,824 shares of company stock valued at $53,611,715. Insiders own 0.16% of the company's stock.

Gilead Sciences Stock Down 2.0 %

Shares of Gilead Sciences stock traded down $2.00 during trading on Friday, hitting $96.04. The company's stock had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $100.51. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company has a fifty day simple moving average of $93.04 and a two-hundred day simple moving average of $86.76. The company has a market capitalization of $119.69 billion, a PE ratio of 1,067.11, a P/E/G ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.29 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.